Stay updated with breaking news from Predict long term. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Data from the ongoing phase 2 trial show that clinicians can use ImPrint, an immune-related biomarker, to identify breast cancer patients who are likely to respond to neoadjuvant immunotherapy. ....